Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company that develops gene therapies for rare and devastating diseases. The company's pipeline includes gene therapies for Fanconi Anemia, Leukocyte Adhesion Deficiency-I, Pyruvate Kinase Deficiency, and Infantile Malignant Osteopetrosis. Rocket Pharmaceuticals' gene therapy platform is based on lentiviral vectors, which are designed to deliver genes to cells to correct genetic defects. The company was founded in 2015 and is headquartered in New York, New York.